WinSanTor is developing a proprietary first-in-class therapy to prevent and reverse nerve damage. Our team has identified a novel biological phenomenon termed “neuronal cholinergic constraint” that inhibits neuronal growth, and is developing compounds that overcome this constraint by promoting nerve recovery after toxic or metabolic injury. Our lead/first compound, WST-057, is a well-characterized, previously approved drug with an established safety history that has been used for many years against an unrelated indication. This allows WinSanTor a direct path to market, reducing development, time, and cost with a drug that is patented as a new formulation with novel indications.
WST-057 is just one compound we are investigating in a family of promising compounds that we have exclusive worldwide rights to. We are strategically expanding WST-057’s indications to all neuropathies, such as chemo-induced peripheral neuropathy (CIPN) and HIV-related peripheral neuropathy (HIV-PN).